数据驱动的时空建模揭示了阿尔茨海默病皮质缩的个性化轨迹
Chunyan Li1, Yutong Mao2, Xiao Liu3
1Department of Mathematics, The Pennsylvania State University, University Park, PA, 16802, USA.
ArXiv
|November 26, 2025
概括
这项研究引入了一个个性化的模型,使用脑部扫描来预测阿尔茨海默病 (AD) 的进展. 该模型准确预测了AD生物标志物和认知衰退,优于目前用于更好的患者分层的方法.
科学领域:
- 神经科学是一个神经科学.
- 医疗成像医学成像
- 计算生物学 计算生物学
背景情况:
- 阿尔茨海默病 (AD) 病理在脑网络中逐渐扩散.
- 预测个体AD的进展仍然是一个重大挑战.
- 目前的方法与个性化轨迹预测扎.
研究的目的:
- 开发一个个性化,基于图形的动态模型来预测阿尔茨海默病 (AD) 的进展.
- 用纵向MRI和PET数据捕捉皮质缩的时空演变.
- 改善个人级别的AD生物标志物和认知衰退预测.
主要方法:
- 从MRI和PET数据构建个性化的大脑图形.
- 开发了一个动态模型来学习区域神经退行模式.
- 将模型应用于来自阿尔茨海默病神经成像计划 (ADNI) 的1891名参与者.
主要成果:
- 该模型准确地预测了关键的AD生物标志物 (粉样β,,神经退行) 和认知.
- 与临床和神经成像基准相比,实现了卓越的性能.
- 比标准生物标志物更有效地确定了不同的患者进展亚型和预期的认知衰退.
结论:
- 基于网络的数字双胞胎框架为AD轨迹预测提供了量化,个性化的方法.
- 证明了改善患者分层和临床试验设计的潜力.
- 突出疾病传播的区域驱动因素,为有针对性的治疗开发提供信息.
更多相关视频
相关概念视频
01:26Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
01:22Alzheimer's Disease: Treatment
772
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
772